Celltrion Group Completes Acquisition of Takeda's 'Primary Care' Business Rights
Takeda Pharmaceutical Rights Sold for Approximately 247.1 Billion KRW
Celltrion Group sold the primary care business rights in the Asia-Pacific region, which it acquired from the multinational pharmaceutical company Takeda Pharmaceutical (Takeda) in 2020, after three years.
On the 18th, Celltrion signed a contract to sell the business rights for primary care over-the-counter (OTC) drugs worth approximately 37 billion KRW to Dongwha Pharm, transferring the business rights for four products including the comprehensive cold medicine 'Hwaituben' and the stomatitis treatment 'Albothyl.'
Following the sale of prescription drug (ETC) rights, Celltrion Group has completed the restructuring of its business by selling OTC business rights totaling 247.1 billion KRW. The ETC segment was sold last year in a contract worth 209.9 billion KRW to CBC Group, a Singapore-based global healthcare private equity firm. Through these two separate sales, Celltrion Group has secured cumulative sales revenue of 141.2 billion KRW in three years.
Celltrion Group plans to secure cash liquidity and focus on the group's future growth by identifying appropriate buyers who can create synergies across business segments and proceeding with the sales process.
Additionally, domestic ETC products were excluded from this split sale, so the business rights for those products will continue to be maintained. The group also secured exclusive rights to supply domestically produced diabetes treatment 'Nesina' and hypertension treatment 'Idalbi' in the Asia-Pacific region, enabling continuous additional revenue generation beyond the sales proceeds.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
A Celltrion Group official stated, "The decision to sell the Takeda primary care business rights, including the ETC business rights, was a strategic judgment to early recover investment profits, focus on the group's core businesses, and seek new growth engines. Going forward, we will accelerate global market entry through active biosimilar portfolio building and innovative drug development, aiming to become a global big pharma that realizes healthy lives for humanity."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
